BRIEF-Novavax Presents Data On Updated Covid-19 Vaccine And Progress To Date On Its Covid-19-Influenza Combination Vaccine Candidate At World Vaccine Congress 2024

Reuters04-01

Novavax Inc :

* NOVAVAX PRESENTS DATA ON UPDATED COVID-19 VACCINE AND PROGRESS TO DATE ON ITS COVID-19-INFLUENZA COMBINATION VACCINE CANDIDATE AT WORLD VACCINE CONGRESS 2024

* NOVAVAX: PARTICIPANTS WHO PREVIOUSLY GOT MRNA VACCINE SHOWED ROBUST NEUTRALIZING ANTIBODY TITERS FOR XBB.1.5 SUBVARIANT AND FOR JN.1 SUBVARIANT

* NOVAVAX INC: DATA ALSO SHOWED THAT VACCINE'S SAFETY AND REACTOGENICITY PROFILE WAS CONSISTENT WITH ITS PROTOTYPE VACCINE (NVX-COV2373)

Source text for Eikon: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2424574150?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-01 23:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2424574150","market":"us","top_or_hot":-1,"title":"BRIEF-Novavax Presents Data On Updated Covid-19 Vaccine And Progress To Date On Its Covid-19-Influenza Combination Vaccine Candidate At World Vaccine Congress 2024","media":"Reuters","content":"<html><body><p>Novavax Inc   :</p><p>   * NOVAVAX PRESENTS DATA ON UPDATED COVID-19 VACCINE AND PROGRESS TO DATE ON ITS COVID-19-INFLUENZA COMBINATION VACCINE CANDIDATE AT WORLD VACCINE CONGRESS 2024</p><p>   * NOVAVAX: PARTICIPANTS WHO PREVIOUSLY GOT MRNA VACCINE SHOWED ROBUST NEUTRALIZING ANTIBODY TITERS FOR XBB.1.5 SUBVARIANT AND FOR  JN.1 SUBVARIANT</p><p>   * NOVAVAX INC: DATA ALSO SHOWED THAT VACCINE'S SAFETY AND REACTOGENICITY PROFILE WAS CONSISTENT WITH ITS PROTOTYPE VACCINE (NVX-COV2373)</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Novavax Presents Data On Updated Covid-19 Vaccine And Progress To Date On Its Covid-19-Influenza Combination Vaccine Candidate At World Vaccine Congress 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Novavax Presents Data On Updated Covid-19 Vaccine And Progress To Date On Its Covid-19-Influenza Combination Vaccine Candidate At World Vaccine Congress 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-01 23:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax Inc   :   * NOVAVAX PRESENTS DATA ON UPDATED COVID-19 VACCINE AND PROGRESS TO DATE ON ITS COVID-19-INFLUENZA COMBINATION VACCINE CANDIDATE AT WORLD VACCINE CONGRESS 2024   * NOVAVAX: ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2424574150","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2424574150","pubTimestamp":1711984205,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Novavax Inc   :   * NOVAVAX PRESENTS DATA ON UPDATED COVID-19 VACCINE AND PROGRESS TO DATE ON ITS COVID-19-INFLUENZA COMBINATION VACCINE CANDIDATE AT WORLD VACCINE CONGRESS 2024   * NOVAVAX: PARTICIPANTS WHO PREVIOUSLY GOT MRNA VACCINE SHOWED ROBUST NEUTRALIZING ANTIBODY TITERS FOR XBB.1.5 SUBVARIANT AND FOR  JN.1 SUBVARIANT   * NOVAVAX INC: DATA ALSO SHOWED THAT VACCINE'S SAFETY AND REACTOGENICITY PROFILE WAS CONSISTENT WITH ITS PROTOTYPE VACCINE Source text for Eikon:    Further company coverage:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4097":"系统软件","NVAX":"诺瓦瓦克斯医药","BK4588":"碎股","BK4568":"美国抗疫概念","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","BK4535":"淡马锡持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BNTX":"BioNTech SE","BK4585":"ETF&股票定投概念","PRGS":"Progress Software Corporation"},"translate_title":"简介——Novavax在2024年世界疫苗大会上展示了最新新冠肺炎疫苗的数据及其新冠肺炎——流感联合疫苗候选疫苗的最新进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1,"NVAX":1,"PRGS":1},"content_text":"Novavax Inc   :   * NOVAVAX PRESENTS DATA ON UPDATED COVID-19 VACCINE AND PROGRESS TO DATE ON ITS COVID-19-INFLUENZA COMBINATION VACCINE CANDIDATE AT WORLD VACCINE CONGRESS 2024   * NOVAVAX: PARTICIPANTS WHO PREVIOUSLY GOT MRNA VACCINE SHOWED ROBUST NEUTRALIZING ANTIBODY TITERS FOR XBB.1.5 SUBVARIANT AND FOR  JN.1 SUBVARIANT   * NOVAVAX INC: DATA ALSO SHOWED THAT VACCINE'S SAFETY AND REACTOGENICITY PROFILE WAS CONSISTENT WITH ITS PROTOTYPE VACCINE (NVX-COV2373)Source text for Eikon:    Further company coverage:","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2424574150"}